ROBUST study: why did it not meet its primary endpoint? A subgroup analysis

4th Workshop : Subgroup AnalysisПодробнее

Interpreting a Subgroup Analysis: Is There a Real Effect?Подробнее

Clinical Updates In Oncology - 27 Dec 2024Подробнее

Dr. Vitolo on What the ROBUST Trial Data Means for ABC-Type DLBCПодробнее

NISS-Merck Meet-Up: "Subgroup Analysis" September, 2019Подробнее

Why Subgroup Analysis Matters: A Case Study for Survey ResearchersПодробнее

Subgroup analysis of ATTRACTION-5: benefit of nivolumab in G/GEJ advanced + PD-L1-positive tumorsПодробнее

Subgroup Analyses: Subpar or Sublime? | NEJM EvidenceПодробнее

NHLBI ICTR Short Video #2, Subgroup Analyses in Clinical TrialsПодробнее

PPCR 2020: question from Talita for lecture 15 -subgroup analysisПодробнее

ASCO 2023 Expert Report on novelties in oncogene driven NSCLC by A. Curioni-FontecedroПодробнее

Examples from clinical trials - S. WassmannПодробнее

HFA 24: MONITOR-HF Subgroup AnalysisПодробнее

Overview of Subgroup AnalysisПодробнее

Rivaroxaban for Reducing Vascular Event Risks after Limb Revascularization for Peripheral Artery ...Подробнее

Examples from clinical trials - S. WassmannПодробнее

Subgroup Analyses in Early Phase Clinical Trials - Bjorn Bornkamp, NovartisПодробнее

Evaluating predictive markers and subgroups in clinical trials: Caution and best practicesПодробнее

RevMan Tutorial - How To Perform Subgroup AnalysisПодробнее